🇺🇸

Index Intelligence

· daily

S&P 500 Technology Sector SEC Filings — March 25, 2026

Across 25 filings in the USA S&P 500 Technology intelligence stream (despite sector mix including non-tech), proxy statements dominate (12/25) signaling AGM season kickoff with May 2026 meetings, emphasizing governance enhancements like board refreshment at Century Communities and Cadence. Financial results show mixed trends: revenue growth in standouts like Adobe (+12% YoY to $6.4B subscription-driven) and Lafayette Square (+50% investment income to $84.7M), contrasted by declines in Dyadic (-12% YoY revenue) and Planet 13 (-11.2% FY revenue). Capital returns remain robust with $144M buybacks at Century Communities, $2.5B repurchases at Adobe, and $0.25 quarterly dividend at Dime Community. Leadership transitions emerge as a theme in tech-relevant names: Adobe CEO Shantanu Narayen stepping down (search underway), TXN SVP retirement, and Muzinich funds' C-suite overhaul. Period-over-period, 4/7 key financial filers posted YoY revenue growth (avg +17%), but margins mixed with Planet 13 improving to 38.6% yet EBITDA flipping to loss; non-tech outliers like Century Communities highlight operational efficiencies (costs -13k/home). Tech sector implications: Adobe's strength and Micron's debt tender signal balance sheet optimization amid AI/semiconductor cycles, positioning for H2 catalysts.

13 high priority 12 medium 25 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 25, 2026

Across 20 NASDAQ-100 related SEC filings from March 25, 2026, key themes include robust capital returns via dividends and buybacks (e.g., Century Communities $178.4M dividends + $144M repurchases, Adobe $2.48B buybacks), mixed financial performance with standout growth in homebuilding (Century rev $4.1B) and software (Adobe +12% YoY rev to $6.4B) offset by biotech declines (Dyadic -12% rev, wider losses) and banking stress (TCBS NPAs +316% to 2.65%). Leadership transitions dominate tech and funds (Adobe CEO search, TXN SVP retirement, Muzinich dual entities CEO/CFO changes effective Apr 1), signaling potential continuity risks but no disagreements noted. Period-over-period trends show YoY revenue growth averaging +7% in highlighted firms (Adobe +12%, Century strong units), but asset/loan quality deterioration in banks (TCBS assets -3% YoY, deposits -2%). Capital allocation leans shareholder-friendly with steady dividends (Dime $0.25, CMC $0.20), while debt actions (Micron tenders, OneMeta $2.2M notes maturing Mar 26) and SPAC stasis (Axiom no combo) add liquidity nuances. Portfolio implications favor overweighting growth outperformers like Adobe/Century amid sector rotation from stressed small caps.

11 high priority 9 medium 20 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 25, 2026

Across 50 SEC filings from S&P 500 Financials and related entities dated March 25, 2026, overarching themes include resilient revenue growth in select tech-adjacent financial services (avg 16% YoY in Pure Storage, UiPath, Braze) offset by margin compression (avg -100bps in Rentokil, Braze, Spectral AI) and persistent SPAC challenges with high redemptions eroding trust balances (e.g., Concord -99.6%, byNordic -53%). Capital allocation leans shareholder-friendly with dividend hikes (Zedge +25% to $0.02/share), buybacks (News Corp $1B program, Chiba Bank ¥14.5B preferred repurchase), and M&A activity (Sandisk $1B Nanya stake at 15% discount, Thermon/CECO merger synergies). Mixed sentiment prevails (28/50 mixed/neutral), with positive signals from profitability turnarounds (UiPath $282M net income vs prior loss) and forward catalysts like AGMs (NOVAGOLD May 14), liquidations (Stratus $29.73-$37.69/share), and Phase 2 trials (Maze Therapeutics mid-2026). Portfolio-level trends show 12/20 revenue reporters growing >10% YoY but 8/15 loss-makers widening deficits amid high opEx (avg +20% in Pure, Braze). Key implications: Favor growth names with cash buffers (Chewy $860M cash, Energous $39.4M post-raise) over liquidity-strapped SPACs; monitor Q2 catalysts for alpha.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 25, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (broadly encompassing food, beverages, household, and related sectors amid mixed filings), overarching themes include modest revenue growth in select REITs and producers (avg +1-15% YoY in AFFO/revenues for Modiv/Global Self/Fresh Del Monte), robust M&A activity (e.g., Fresh Del Monte's $285M Del Monte assets acquisition), stable dividend declarations (Armour $0.24/share, Global Self $0.0725/qtr), and neutral compliance-heavy trust/SPAC reports dominating volume. Period-over-period trends show mixed results: AFFO/FFO growth (Modiv +15.1% YoY, Global Self +3.4%) offset by net income declines (Modiv -91.5%, Global Self -4%) and impairments, with Consumer Staples standouts like Fresh Del Monte and Hershey showing expansion via deals/proxies. Critical developments include positive merger synergies (Thermon/CECO), FDA priority review (Celcuity PDUFA Jul 17, 2026), and NYSE delisting risks (SelectQuote), implying sector resilience in branded foods amid macro pressures but vigilance on REIT-like exposures misaligned with staples. Portfolio-level patterns reveal 4/10 key filings with YoY revenue/NOI stability (+0.6-1.4%), dividend commitment signaling conviction, and upcoming catalysts in meetings/M&A closings driving near-term alpha.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 25, 2026

Across the 50 filings in the USA S&P 500 Industrials intelligence stream (broadly encompassing aerospace, defense, machinery, transportation, construction, and adjacent sectors), sentiment is mixed with 14 positive, 16 mixed, and 20 neutral/bearish outcomes, highlighting revenue resilience in select industrials (Winnebago +6% QoQ, Generac $4.2B FY sales) amid broader challenges in adjacent biotech/pharma and financials. Key period-over-period trends include revenue growth averaging +12% YoY in growth outperformers (Pure Storage +16%, Local Bounti +27%, ECB Bancorp NII +29%), but persistent net losses in biotech (Kiora -$10.8M vs +$3.6M prior, Armata -$173M), margin pressures (Pure Storage opex +17-20%), and asset quality deterioration (Texas Community NPA +316%). Critical developments feature M&A momentum (Fresh Del Monte $285M acquisition, Merck/Terns $6.7B at 31% premium), dividend hikes signaling confidence (Zedge +25% to $0.02, Parke $0.18), and SPAC trust balances exceeding $230M (Aldel $243M, Range $232M). Capital allocation favors returns (3M $4.8B dividends/buybacks, Armour $0.24 monthly div), with forward catalysts clustered in May 2026 proxy meetings and Q2-Q3 pharma readouts. Portfolio-level patterns show industrials/transport outperforming (e.g., Winnebago profitable turnaround) versus biotech drags, implying selective rotation into revenue growers with strong balance sheets.

32 high priority 18 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 25, 2026

Across the 7 filings in the USA S&P 500 Energy stream, dominant themes include neutral governance updates (board retirements at ONEOK, bylaws amendments at Chevron, proxy solicitations at Chesapeake Utilities) with low-to-moderate materiality, contrasted by mixed sentiment in non-core IPO registrations (AsiaPac AdTechinno, Texxon Holding) highlighting controlled company structures and growth funding needs. Kaanapali Land's 10-K reveals deteriorating financials with net loss widening to $3.7M (-236% YoY from $1.1M), revenues down 16% YoY to $1.6M, cash -32% to $15.8M, and operating cash use doubling to $5.9M, marking a clear underperformer. No insider trading activity reported across filings; capital allocation shows stable distributions at Kaanapali ($0.9M in 2025 vs $0.8M prior). Forward-looking catalysts cluster in Q2 2026: annual meetings (ONEOK May 20, CPK May 6), Texxon trial production April 2026, and pending IPOs. Portfolio-level trends limited by sparse metrics, but Kaanapali's margin improvements via 26% YoY op ex cut signal cost discipline amid revenue weakness. Overall neutral sector tone implies low volatility, with alpha in monitoring governance transitions and IPO dilutions risks.

5 high priority 2 medium 7 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 25, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (period March 25, 2026), mixed financial results dominate with 12/20 10-K/10-Q filings showing revenue/AFFO growth (avg +12% YoY) offset by net income declines (avg -45% YoY) due to impairments and one-offs in REITs and industrials. Positive catalysts include raised guidance (e.g., Karman +53% revenue), M&A synergies (Thermon/CECO), and capital returns ($4.8B at 3M, $500M+ at Enact), while proxy season ramps up with 15+ AGMs in May 2026 featuring stock splits, say-on-pay, and director elections. REITs like Modiv (+15% AFFO) and Global Self Storage (+1.4% revenue, 93% occupancy) highlight operational resilience amid asset sales, but banks face nonperforming asset spikes (e.g., Texas Comm +316%). Overall sentiment skews mixed/neutral (28/50), with bullish outliers in growth sectors (space/defense, pharma) signaling portfolio rotation opportunities. Key implications: Favor companies with strong backlogs/guidance over those with impairments; monitor May catalysts for governance shifts and capital allocation updates.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 25, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary intelligence stream (despite diverse inclusions like SPACs, financials, and tech), proxy season dominates with 10+ DEF 14A/DEFA14A filings scheduling May 2026 annual meetings for director elections, auditor ratifications, and say-on-pay votes, signaling routine governance stability. Period-over-period trends show mixed revenue performance: growth in Cognyte (+14% YoY to $400M), Rentokil (+4% YoY to $6.9B), Jefferies (+27% YoY to $2B), but declines in Marchex (-6% FY to $45.4M), Marpai (-36% to $18.1M), Global Self Storage Q4 (-0.9% rev). Capital allocation leans positive with dividend hikes (Zedge +25% to $0.02, Omega Flex $0.34 quarterly) and buybacks (Jefferies auth +$250M), alongside acquisitions like Fresh Del Monte's $285M Del Monte assets deal. No widespread insider trading patterns, but board appointments (HBT Financial, Better Home) indicate strengthening governance. Forward-looking highlights include Marchex's positive 2026 guidance (Q1 Adj EBITDA +$0.5M, 10% run-rate rev growth) and SPAC timelines (24-month combo windows). Overall, sector shows resilient consumer plays amid volatility, with opportunities in M&A and dividends but risks from margin pressures (Rentokil op profit -9%) and delisting threats.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 25, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (with broader market context), key themes include robust revenue growth in select non-healthcare adjacents like financials (Jefferies +27% YoY Q1 rev to $2B) and pet/health retail (Chewy +6.2% FY25 sales to $12.6B), contrasted by biotech losses widening amid R&D surges (ProMIS -214% R&D to $33M, net loss $39.7M; Precigen net loss to $429M on SG&A +70%). Capital allocation favors shareholders with dividends (Jefferies $0.40/share, HBT Financial board add) and buybacks (Jefferies $250M increase, News Corp $1B program). M&A activity signals consolidation (Danaher $9.9B Masimo acquisition, Lifeward Oratech amendment, Cintas UniFirst). Healthcare biotechs show pipeline progress (ProMIS Phase 1b enrollment complete, data Q3 2026; Precigen PAPZIMEOS J-code Apr 1 2026) despite cash burns. Board changes and proxy meetings cluster in May 2026, indicating governance refreshes. Overall, mixed sentiment (14/50 positive/mixed bullish drivers vs. biotech deterioration), with portfolio-level revenue growth avg +15% YoY in reporting firms but margin volatility (-150bps Chewy GAAP, +60bps gross). Actionable: Favor capex-efficient growers like Chewy (FCF +24% to $562M) over high-burn biotechs pending catalysts.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 24, 2026

Across the four filings in the USA S&P 500 Technology stream, dominant themes include deleveraging and operational restructuring at Ucommune International Ltd, uplisting ambitions at First Northern Community Bancorp, and routine organizational and funding disclosures from Capital One Multi Asset Execution Trust and Federal Home Loan Bank of San Francisco. Ucommune reported sharp YoY declines with revenue down 66% to RMB 26.1M and total assets -38% to RMB 202.5M, but offset by cash +44% to RMB 36.1M, liabilities -57% to RMB 74.2M, operating loss narrowed 12% to RMB 40.6M, and net loss improved 51% to RMB 39.3M following VIE deconsolidation. First Northern's Nasdaq uplisting application signals growth intent, while FHLB SF's $371.5M bond issuance reflects stable funding at 4.000%-4.520% coupons with maturities 2027-2031. Capital One Trust filing is benign with no financial metrics. Portfolio-level patterns show 1/4 filings with improving loss metrics amid declines (outlier Ucommune turnaround), no insider activity or capital allocation trends, and neutral/mixed sentiment overall. Market implications favor monitoring uplisting catalysts and deleveraging for relative outperformance versus stagnant peers.

2 high priority 2 medium 4 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 24, 2026

The 7 filings reveal a bifurcated landscape in the NASDAQ-100 stream, with bullish operational and governance momentum in tech/AI (AITX, Intel) and uplisting potential (First Northern) offsetting sharp financial contraction at Ucommune and neutral housekeeping elsewhere. Key period-over-period trend outlier: Ucommune's revenue plunged 66% YoY to RMB 26.1M and assets declined 38% YoY to RMB 202.5M, though losses narrowed (operating -12% YoY to RMB 40.6M, net -51% YoY to RMB 39.3M) post-VIE deconsolidation. Positive sentiments dominate new filings (AITX expansion, Intel 'Reinventing' progress with Intel 18A/14A advancements, First Northern Nasdaq application), signaling portfolio-level growth in AI/security and governance refresh amid limited broader metrics. Critical developments include Intel's May 13, 2026 AGM for director elections and stockholder proposals on China/human rights risks, and FHLB's $371.5M bond issuance at 4.000-4.520% rates. Market implications: Favor AI/geographic expansion plays and monitor uplisters for liquidity alpha, while de-risking from Chinese-linked distress like Ucommune; no widespread margin/revenue trends due to sparse financial disclosures across filings.

3 high priority 4 medium 7 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 24, 2026

Across 50 filings from S&P 500 Financials and adjacent sectors, proxy statements dominate (e.g., DEF 14A/DEFA14A) with neutral-to-positive governance themes, emphasizing independent boards, stock ownership compliance, and say-on-pay votes ahead of Apr-May 2026 AGMs. Revenue growth is a bright spot in 8/50 filings, averaging +52% YoY (e.g., Paysign +40.5%, FTC Solar +110.5%, Concentrix +5.4%), but profitability mixed with 6/12 earnings reporters showing margin compression (avg -150 bps) and widening losses (e.g., Achieve Life +37% YoY net loss, Vertical Aerospace op loss +108%). Capital allocation favors returns: dividends declared (Braemar, Concentrix), buybacks ($1B News Corp, Flowco $16.5M repurchase), note redemptions (Ready Capital). M&A catalysts include American Water's $Essential Utilities merger (Q1 2027 close) and Fundrise eREIT consolidations; Galaxy entities' 13Fs reveal heavy crypto/mining bets ($173M-$137B AUM across quarters). REITs shine (CareTrust +17% Normalized FFO, $1.76B deployment), but covenant waivers (FTC Solar, Inotiv) and going concerns (Ocean Thermal, Vertical) flag liquidity risks. Forward catalysts cluster in H1 2026: PDUFAs, AGMs, rate cases.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 24, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (broadly encompassing food, beverages, household, personal care, and adjacent sectors), dominant themes include neutral-to-positive compliance assertions in 15+ mortgage trusts (e.g., Benchmark, JPMDB, CF series), signaling stable ABS servicing with no material non-compliance. Period-over-period trends show mixed performance: robust growth in outliers like Cadeler A/S (profit +330% YoY to €280M, EBITDA +238% to €425M) and Select Water Solutions (segment revenues +19% YoY), contrasted by declines in G-III Apparel (net sales -7% YoY to $2.96B, op profit -63%) and Velo3D (Q4 rev -25% YoY, gross margin -73.6%). Capital allocation highlights dividend declarations (Braemar Hotels) and debt refinancings (Moog +5.5% notes, Kodiak 5.875% notes), while M&A speculation emerges in Estée Lauder (potential Puig merger, materiality 9/10). Portfolio-level patterns reveal 6/10 high-materiality filings with mixed sentiment due to growth-margin tradeoffs, 12+ proxy statements clustering AGMs in May 2026 for governance catalysts, and financing inflows supporting expansion amid rising indebtedness (e.g., Cadeler debt to €1.46B). Overall, actionable intelligence points to monitoring beauty M&A and energy-adjacent growth amid apparel weakness, with no widespread insider selling but leadership transitions signaling potential volatility.

39 high priority 11 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 24, 2026

Across 50 filings in the USA S&P 500 Industrials intelligence stream (broadly encompassing aerospace, defense, machinery, transportation, construction, with extraneous financial/mortgage trusts and proxies), overarching themes include routine Regulation AB compliance affirmations in 15+ mortgage trusts (all neutral/positive, no non-compliance), proxy season ramp-up for May 2026 AGMs (10+ filings), and mixed financial results in operating companies highlighting resilience in transportation (C.H. Robinson EPS +25.1% YoY despite revenues -8.4%) amid broader sector softness. Period-over-period trends reveal divergent performance: explosive growth in niche players like Cadeler A/S (profit +330% YoY to €280.2M, EBITDA +238%) and Fennec Pharmaceuticals (product sales +50% YoY to $44.6M), contrasted by declines in apparel/transport (G-III sales -7% YoY, Neurogene net loss widened 20% YoY to $90.4M). No insider trading activity disclosed across filings, limiting conviction signals; capital allocation shows distributions funded by cash flows (Cantor Fitzgerald) or proceeds (Strategic Storage +8.6% YoY), with debt increases (Cadeler net indebtedness +181% to €1.46B). Critical developments include M&A discussions (Estée Lauder/Puig), leadership transitions (Bitcoin Depot new CEO, QuidelOrtho CLO), and clinical catalysts (Neurogene Embolden trial dosing Q2 2026). Portfolio-level patterns flag Industrials outperformance in profitability metrics vs. revenue (e.g., C.H. Robinson ops income +18.8% YoY), with opportunities in undervalued turnarounds amid proxy-driven governance focus.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 24, 2026

Across the S&P 500 Energy sector filings, key themes include management continuity at Chesapeake Utilities (CPK) via a seamless CFO transition and Devon's proactive balance sheet strengthening through credit extension and merger progress with Coterra. No period-over-period declines, flat metrics, or adverse financial trends were reported in any filing, signaling operational stability amid positive sentiments in 2/3 filings. Devon's dual filings highlight material catalysts: a tax-free merger targeted for Q2 2026 close and credit maturity extension to March 24, 2031, with potential borrowing cost reductions via 10bps SOFR spread removal. CPK's executive change underscores confidence in sustained earnings growth and balance sheet strength post-transition on July 1, 2026. Portfolio-level implications point to improving liquidity and M&A momentum in oil & gas E&P, positioning Devon as a sector consolidator while CPK exemplifies utility-like stability in energy distribution. Overall, bullish undertones dominate with no guidance cuts or insider selling detected.

2 high priority 1 medium 3 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 24, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily small/mid-cap and trusts with DJ30-adjacent themes like Intel, eBay), overarching themes include biotech regulatory catalysts, SPAC/M&A pursuits, private credit expansions, energy trust depletions, and governance proxies. Period-over-period trends reveal bimodal patterns: explosive growth in AI/biotech (Blaize revenue +24x YoY to $38.6M, Audax portfolio +46% to $949.8M) contrasted by sharp declines in energy royalties (MV Oil income -39% YoY to $11.3M, VOC -37% to $8.6M) and biotech losses (Achieve +37% to $54.6M). Credit funds show portfolio growth but yield compression (Audax 8.28% vs 10.07% prior), while SPACs highlight PIPE evaluations amid redemption risks. Critical developments: Achieve PDUFA June 20 2026, Blaize FY26 $130M revenue guide, Thermon/CECO merger synergies for 20%+ EBITDA. Portfolio-level patterns: 6/10 high-materiality mixed sentiments driven by cash raises vs burns; capital allocation favors distributions (Golub $0.1875/share) over buybacks; no widespread insider trading but heavy shelves/ATMs signal dilution risks. Market implications: Bullish AI/biotech catalysts, bearish energy depletion, monitor SPAC closings for volatility.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 24, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary stream (broadly encompassing retail, services, and adjacent sectors), overarching themes include robust revenue growth in select growth names (avg +50% YoY across 12 cos with data, e.g., FTC Solar +110.5%, Fennec +50%) offset by widening net losses (avg +40% YoY in 10 cos) due to op ex surges (e.g., Achieve +41%) and one-time hits; heavy capital allocation toward buybacks (Robinhood +$1.5B) and dividends (Braemar, Golub); M&A/reorg activity (UniFirst/Cintas H2 2026 close, Fundrise mergers, Digimarc reorg); and a wave of proxy filings signaling April-May 2026 meetings. Period-over-period trends reveal portfolio expansion in credit funds (Audax +46%, HPS +118%) and improving cash in biopharma (Achieve +64% cash), but deteriorating margins in solar/manufacturing amid debt pressures. Critical developments like Achieve's PDUFA June 20, 2026, and FTC Solar's covenant waivers imply near-term catalysts, while multiple CFO resignations at New Mountain entities signal leadership flux. Sector implications point to resilient consumer-related demand (e.g., G Willi Food +6% rev, +29% NI) but vulnerability to costs/debt in cyclical plays, favoring buyback-heavy names for near-term returns.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 24, 2026

Across the USA S&P 500 Healthcare stream's 36 filings, biotech and medtech firms dominate with mixed sentiment: clinical advancements and FDA milestones offset widening net losses (avg +25% YoY across Achieve, Absci, Artelo) driven by 25-40% YoY op ex surges amid flat/declining revenues. S&P 500 heavyweights like Medtronic, Centene, and Thermo Fisher show strategic progress—FDA clearance, leadership promotions, and M&A completion—but face short-term EPS dilution and charges. Cash positions strengthened via financings (e.g., Absci $144M to H1 2028, Achieve $36M up 6% YoY), supporting runways through 2027-2028, while capital allocation leans toward R&D reinvestment over dividends/buybacks. Key portfolio trends: 4/7 core healthcare cos reported loss expansion despite asset growth (avg +5% YoY), with H1-H2 2026 catalysts clustering around PDUFAs, trial data, and launches. Non-health filings (e.g., mortgage trusts, FHLBs) neutral, highlighting compliance and debt issuance but irrelevant to sector. Implications: tactical longs on catalysts, hedge burn risks; relative outperformance in clinical progress vs. financial deterioration.

20 high priority 16 medium 36 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 23, 2026

Across 50 SEC filings dated March 23, 2026, in the USA S&P 500 Consumer Staples stream (with broader context), dominant themes include a surge in proxy statements (DEF 14A/DEFA14A for ~20 companies) preparing for May 2026 annual meetings, M&A and restructuring activity (e.g., CECO-Thermon merger with $40M synergies, RMBI-Farmers $82.4M deal, Honeywell Aerospace spin-off via $10B debt tender), and mixed FY25 financials where reported: revenue growth in outliers like CECO (+39% YoY to $774M, EBITDA +43% to $90M), US Antimony (+163% YoY to $39.3M), but declines in Aspen Aerogels (-40% YoY to $271.1M, $389.6M net loss) and Kimberly-Clark (-2.1% net sales to $16.4B despite +1.7% organic). Consumer Staples highlights show resilience via KMB's 54th consecutive dividend increase and $32B Kenvue acquisition (H2 2026 close), offset by Limoneira's dividend pause for capex. Period-over-period trends reveal volatility (avg reported rev change +300% skewed by small caps, but staples flat/declining), with positive capital allocation in dividends/buybacks absent specifics, and forward catalysts clustering in Q2 2026 (AGMs, mergers). Portfolio implications: Staples defensive amid macro but watch organic growth; alpha in M&A synergies and spin-offs.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 23, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly encompassing aerospace, machinery, and adjacent sectors), key themes include robust M&A and spin-off activity (e.g., Honeywell Aerospace spin, Sealed Air acquisition), SPAC extensions/mergers, and mixed financial results with revenue growth in 7/15 reporting companies averaging +35% YoY (e.g., Arbutus +128%, SolarEdge +31%) offset by persistent losses and cash burn in biotechs/small caps. Period-over-period trends show margin improvements in 5 cases (e.g., Bionano gross margin to 46% from 1%, Cato FY SG&A to 35% from 36%), but declines in others (Core Labs op income -3.6% YoY, Cabaletta net loss +45%). Capital allocation leans toward buybacks/repurchases (Slide $125M, Guardian 1.8M shares) and debt refinancings (Hewlett Packard $2B notes, Waters $3.5B), signaling confidence amid high interest environments. Forward-looking catalysts cluster in 2H 2026 (Phase 3 trials, Nasdaq compliances), with positive regulatory clearances (Faraday SEC no-action) removing overhangs. Portfolio-level, industrials show relative strength in cap allocation vs. small-cap dilution risks, positioning sector for consolidation-driven alpha.

24 high priority 26 medium 50 total filings